Ordering
Available Variants5 mg
CHA.88197-5mg
Price
€61.52
Available – Dispatch in 14 days
25 mg
CHA.88197-25mg
Price
€210.80
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.88197-5mg | €61.52 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.88197-25mg | €210.80 |
≥98% (HPLC), KCC2 inhibitor, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C19H18N4OS2 |
|---|---|
| CAS Number | 1391737-01-1 |
| Molecular Weight | 382.50 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD30182240 |
| NACRES | NA.21 |
| Assay | ≥98% (HPLC) |
| Form | powder |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
VU0463271, also known by its CAS number 1391737-01-1, is a potent and selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor. This compound has been shown to exhibit high affinity for the M1 receptor, with minimal activity at other muscarinic receptor subtypes. In vitro studies have demonstrated that VU0463271 can enhance the activity of acetylcholine at the M1 receptor, leading to increased signaling and potential therapeutic effects. The compound has been investigated as a potential treatment for various neurological and psychiatric disorders, including Alzheimers disease, schizophrenia, and cognitive impairment. Further research is needed to fully elucidate the pharmacological profile and potential clinical applications of VU0463271, but its unique mechanism of action and selective receptor modulation make it an interesting candidate for further development. Its potential therapeutic benefits are currently being explored in ongoing studies.
